Brokerages Set Xencor Inc (XNCR) Target Price at $29.40
Shares of Xencor Inc (NASDAQ:XNCR) have been assigned an average rating of “Buy” from the eight brokerages that are currently covering the company. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $28.60.
Several analysts recently commented on the stock. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Nomura assumed coverage on shares of Xencor in a research note on Wednesday, March 1st. They set a “neutral” rating on the stock. Wedbush restated an “outperform” rating and set a $33.00 target price (up previously from $27.00) on shares of Xencor in a research note on Thursday, March 2nd. Finally, Instinet began coverage on shares of Xencor in a research note on Wednesday, March 1st. They issued a “neutral” rating and a $21.00 price objective on the stock.
Xencor (NASDAQ:XNCR) traded down 0.32% during midday trading on Tuesday, reaching $21.84. 84,863 shares of the company traded hands. The company has a 50 day moving average of $23.50 and a 200-day moving average of $24.25. Xencor has a 12-month low of $12.51 and a 12-month high of $29.38. The stock has a market capitalization of $1.02 billion, a P/E ratio of 61.87 and a beta of 2.21.
Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.06. The business had revenue of $4.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a return on equity of 22.09% and a net margin of 39.33%. Equities analysts anticipate that Xencor will post ($1.21) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Xencor Inc (XNCR) Target Price at $29.40” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/05/19/xencor-inc-xncr-given-average-recommendation-of-buy-by-analysts-updated.html.
In related news, insider Edgardo Baracchini, Jr. sold 10,568 shares of Xencor stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $26.01, for a total value of $274,873.68. Following the completion of the sale, the insider now directly owns 9,818 shares in the company, valued at $255,366.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Edgardo Baracchini, Jr. sold 1,821 shares of Xencor stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $25.00, for a total value of $45,525.00. Following the completion of the transaction, the insider now owns 1,821 shares in the company, valued at approximately $45,525. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,293 shares of company stock valued at $710,239. 4.03% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the company. Gotham Asset Management LLC raised its stake in shares of Xencor by 590.6% in the third quarter. Gotham Asset Management LLC now owns 161,180 shares of the biopharmaceutical company’s stock worth $3,947,000 after buying an additional 137,842 shares in the last quarter. HBK Investments L P purchased a new stake in shares of Xencor during the third quarter worth approximately $1,178,000. Zacks Investment Management bought a new position in shares of Xencor during the third quarter worth about $249,000. Citadel Advisors LLC bought a new position in shares of Xencor during the third quarter worth about $1,204,000. Finally, Piermont Capital Management Inc. bought a new position in shares of Xencor during the third quarter worth about $615,000. Institutional investors and hedge funds own 64.14% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Stock Ratings for Xencor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc and related stocks with our FREE daily email newsletter.